Medical Cannabis: Vulnerable Populations, Mental Health Conditions

Shanna Babalonis, Ph.D.
University of Kentucky
College of Medicine
Department of Behavioral Science
Center on Drug and Alcohol Research
Medical Cannabis & Psychiatric Conditions

Overall, we know very little about medical cannabis and how it affects vulnerable populations, including those with psychiatric conditions.
Cannabinoids: Schizophrenia, Psychosis

- Endocannabinoid dysregulation has been detected in patients with schizophrenia and psychosis

- Cannabis associated with earlier psychosis episode in adolescents (association only)

- Cannabis use a risk factor for psychosis in those pre-disposed

- Several studies reported decreased anandamide concentrations of CSF in patients compared to controls; this appears to normalize with non-cannabinoid treatment; limitations to these studies (e.g., concomitant cannabis use)

- Cannabidiol (CBD) being explored as a treatment (some positive results in early studies; not conclusive) (see Leweke et al., 2018)

- Psychosis symptoms are more severe in patients that smoke marijuana compared to patients who have stopped or who have never used marijuana (Setien-Suero, 2019)
Anxiety

-Many anecdotal reports that cannabidiol (CBD) alleviates anxiety (overall, appears to be the primary reason individuals report taking non-Rx CBD)
-Not well-established in the literature (little to no evidence in high quality studies in humans)

-Medical cannabis also reported to have some anxiolytic effects
-However, can also induce anxiety/panic as an acute reaction (along with tachycardia which can worsen anxiety reaction)
-No high-quality, placebo-controlled studies have thoroughly examined cannabis or CBD effects on anxiety – data desperately needed